Compounds > uk-432097
Page last updated: 2024-11-11

uk-432097

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

UK-432097: a highly potent and selective agonist and drug candidate for chronic obstructive pulmonary disease (COPD) treatment; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9833519
CHEMBL ID1096896
SCHEMBL ID726361
MeSH IDM0557197

Synonyms (39)

Synonym
uka ,
6-(2,2-diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]-n-[2-[(1-pyridin-2-ylpiperidin-4-yl)carbamoylamino]ethyl]purine-2-carboxamide
uk432097
CHEMBL1096896 ,
6-(2,2-diphenylethylamino)-9-((2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-n-(2-(3-(1-(pyridin-2-yl)piperidin-4-yl)ureido)ethyl)-9h-purine-2-carboxamide
bdbm50316212
uk-432,097
380221-63-6
beta-d-ribofuranuronamide, 1-deoxy-1-(6-((2,2-diphenylethyl)amino)-2-(((2-((((1-(2-pyridinyl)-4-piperidinyl)amino)carbonyl)amino)ethyl)amino)carbonyl)-9h-purin-9-yl)-n-ethyl-
unii-8l3oaj1r5a
uk-432097
8l3oaj1r5a ,
6-((2,2-diphenylethyl)amino)-9-(n-ethyl-beta-d-ribofuranosyluronamide)-n-(2-(n'-(1-(2-pyridyl)-4-piperidyl)ureido)ethyl)-9h-purine-2-carboxamide
6-((2,2-diphenylethyl)amino)-9-(n-ethyl-.beta.-d-ribofuranosyluronamide)-n-(2-(n'-(1-(2-pyridyl)-4-piperidyl)ureido)ethyl)-9h-purine-2-carboxamide
.beta.-d-ribofuranuronamide, 1-deoxy-1-(6-((2,2-diphenylethyl)amino)-2-(((2-((((1-(2-pyridinyl)-4-piperidinyl)amino)carbonyl)amino)ethyl)amino)carbonyl)-9h-purin-9-yl)-n-ethyl-
SCHEMBL726361
6-[(2,2-diphenylethyl)amino]-9-{(2r,3r,4s,5s)-5-[(ethylamino)carbonyl]-3,4-dihydroxytetrahydro-2-furanyl}-n-{2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl}-9h-purine-2-carboxamide
6-[(2,2-diphenylethyl)amino]-9-[(2r,3r,4s,5s)-5-[(ethylamino)carbonyl]-3,4-dihydroxytetrahydro-2-furanyl}-n-{2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl]-9h-purine-2-carboxamide
6-[(2,2-diphenylethyl)amino]-9-{(2r,3r,4s,5s)-5-[(ethylamino)carbonyl]-3,4-dihydroxytetrahydro-2-furanyl}-n-{2-[({[-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl}-9h-purine-2-carboxamide
6-[(2,2-diphenylethyl)amino]-9-{(2r,3r,4s,5s)-5-[(ethylamino)carbonyl]-3,4-dihydroxytetrahydro-2-furanyl]-n-{2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl}-9h-purine-2-carboxamide
ZOTHAEBAWXWVID-HXEFRTELSA-N ,
6-[(2,2-diphenylethyl)amino]-9-{(2r,3r,4s,5s)-5-[(ethylamino)carbonyl]-3,4-dihydroxytetrahydro-2-furanyl}-n-(2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl)-9h-purine-2-carboxamide
6-[(2,2-diphenylethyl)amino]-9-{(2r,3r,4s,5s)-5-[(ethylamino)carbonyl]-3,4-dihydroxytetrahydro-2-furanyl}n-{2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl}-9h-purine-2-carboxamide
3QAK
uk 432097
6-[2,2-di(phenyl)ethylamino]-9-[(2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]-n-[2-[(1-pyridin-2-ylpiperidin-4-yl)carbamoylamino]ethyl]purine-2-carboxamide
gtpl8420
uk432,097
DTXSID70431408
DB12691
6-[(2,2-diphenylethyl)amino]-9-[(2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl]-n-[2-({[1-(pyridin-2-yl)piperidin-4-yl]carbamoyl}amino)ethyl]-9h-purine-2-carboxamide (non-preferred name)
6-((2,2-diphenylethyl)amino)-9-((2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-n-(2-(3-(1-(pyridin-2-yl)piperidin-4-yl)ureido)ethyl)-9h-purine-2-carboxamide
Q6592047
6-(2,2-diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]-n-[2-[(1-pyridin-2-ylpiperidin-4-yl)carbamoylamino]ethyl]purine-2-carboxamide
beta-d-ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[2-[[[[1-(2-pyridinyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]amino]carbonyl]-9h-purin-9-yl]-n-ethyl-
HY-107046
CS-0027205
E99036
AKOS040749703

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacological and pharmacokinetic SAR of a series of inhaled A(2A) agonists is described leading through to human pharmacokinetic data for a clinical candidate."( SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
Batchelor, DV; Chavaroche, H; Lemaitre, A; Macintyre, F; Mantell, SJ; Maw, GN; Monaghan, SM; Rozze, S; Selby, MD; Stephenson, PT; Stuart, EF; Trevethick, MA; Walker, DK; Whitlock, L; Wright, KN; Wright, PA; Yeadon, M, 2009)		0.35
"Prediction of pharmacokinetic (PK) profile for inhaled drugs in humans provides valuable information to aid toxicology safety assessment, evaluate the potential for systemic accumulation on multiple dosing and enable an estimate for the clinical plasma assay requirements."( A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats.
Harrison, A; Jones, RM, 2012)		0.38

Bioavailability

ExcerptReferenceRelevance
" Administering as a dry powder formulation slowed the rat lung absorption rate of the least soluble compound (fluticasone propionate), impacting the prediction of C(max) and MRT."( A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats.
Harrison, A; Jones, RM, 2012)		0.38

Dosage Studied

ExcerptRelevanceReference
"Prediction of pharmacokinetic (PK) profile for inhaled drugs in humans provides valuable information to aid toxicology safety assessment, evaluate the potential for systemic accumulation on multiple dosing and enable an estimate for the clinical plasma assay requirements."( A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats.
Harrison, A; Jones, RM, 2012)		0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Adenosine receptor A2a,lysozyme chimeraTequatrovirus T4Ki0.00470.00470.00470.0047AID977610
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)IC50 (µMol)0.00400.00052.773925.1700AID477377
Adenosine receptor A2aHomo sapiens (human)IC50 (µMol)0.00400.00071.559410.0000AID477377
Adenosine receptor A2aHomo sapiens (human)Ki0.00400.00001.06099.7920AID1201434; AID647885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Processvia Protein(s)Taxonomy
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID477384Dose normalized fCmax in human at 400 ug administered by aerosol device measured up to 4 hrs (dose normalized to 1 mg/kg)2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID477378Intrinsic clearance in human liver microsomes2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID477390Toxicity in human assessed as increase of sitting blood pressure at 200 to 1600 ug administered by aerosol device2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID477391Inhibition of capsaicin-induced bronchoconstriction in guinea pig at 10 ug up to 8 hrs2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID477381Dose normalized fCmax in rat (dose normalized to 1 mg/kg)2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID647885Binding affinity to A2A adenosine receptor2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.
AID477385Dose normalized fCmax in human at 800 ug administered by aerosol device measured up to 4 hrs (dose normalized to 1 mg/kg)2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID477379Unbound clearance in rat at 1 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID477383Dose normalized fCmax in human at 200 ug administered by aerosol device measured up to 4 hrs (dose normalized to 1 mg/kg)2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID477386Dose normalized fCmax in human at 1600 ug administered by aerosol device measured up to 4 hrs (dose normalized to 1 mg/kg)2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID477389Half life in human at 100 to 1600 ug administered by aerosol device2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID477382Dose normalized fCmax in human at 100 ug administered by aerosol device measured up to 4 hrs (dose normalized to 1 mg/kg)2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID477380Lipophilicity, log D at pH 7.42009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID1201434Binding affinity to human adenosine A2A receptor2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor.
AID477377Agonist activity at adenosine A2A receptor in fMLP-stimulated human neutrophils assessed as inhibition of superoxide production by colorimetric analysis2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
AID1345618Human A2A receptor (Adenosine receptors)2012British journal of pharmacology, Jul, Volume: 166, Issue:6
Functional efficacy of adenosine A₂A receptor agonists is positively correlated to their receptor residence time.
AID1345618Human A2A receptor (Adenosine receptors)2011Science (New York, N.Y.), Apr-15, Volume: 332, Issue:6027
Structure of an agonist-bound human A2A adenosine receptor.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2011Science (New York, N.Y.), Apr-15, Volume: 332, Issue:6027
Structure of an agonist-bound human A2A adenosine receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's7 (77.78)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.41 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.53 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		2.1310amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
albuterol
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).		2.0710phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
activins
Activins: Activins are produced in the pituitary, gonads, and other tissues. By acting locally, they stimulate pituitary FSH secretion and have diverse effects on cell differentiation and embryonic development. Activins are glycoproteins that are hetero- or homodimers of INHIBIN-BETA SUBUNITS.		2.1310
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		2.2110adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
salmeterol xinafoate
Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.		2.0710naphthoic acid
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		3.3660adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.06101,2,3-triazole
zm 241385
ZM 241385: a high affinity radioligand selective for the A2a adenosine receptor		2.0610diamino-1,3,5-triazine
regadenoson
[no description available]		2.4920purine nucleoside
adenosine-5'-(n-ethylcarboxamide)
Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.		2.7930adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-n-ethylcarboxamidoadenosine
2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-N-ethylcarboxamidoadenosine: structure given in first source		2.0710
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine: A2 adenosine receptor agonist; structure given in first source. CGS-21680 : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and the hydrogen at position 2 on the adenine is replaced by a 4-(2-carboxyethyl)phenethylamino group.		2.4920adenosines;
dicarboxylic acid monoamide;
monocarboxylic acid		adenosine A2A receptor agonist;
anti-inflammatory agent
11-cis-retinal
Rhodopsin: A purplish-red, light-sensitive pigment found in RETINAL ROD CELLS of most vertebrates. It is a complex consisting of a molecule of ROD OPSIN and a molecule of 11-cis retinal (RETINALDEHYDE). Rhodopsin exhibits peak absorption wavelength at about 500 nm.. 11-cis-retinal : A retinal having 2E,4Z,6E,8E-double bond geometry.		2.0610retinalchromophore;
human metabolite;
mouse metabolite
harmine
Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.		2.1310harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
pulmicort
Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.		2.071011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
fluticasone
Fluticasone: A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.. fluticasone : A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis.		2.071011beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
binodenoson
[no description available]		2.4920
atl 146e
BMS-068645: structure in first source		2.4920
cangrelor
cangrelor: platelet P(2T) receptor antagonist. cangrelor : A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.		2.2110adenosine 5'-phosphate;
aryl sulfide;
nucleoside triphosphate analogue;
organochlorine compound;
organofluorine compound;
secondary amino compound		P2Y12 receptor antagonist;
platelet aggregation inhibitor
a 134974
A 134974: structure in first source		2.1310
2-(2-(4-chlorophenyl)ethoxy)adenosine
2-(2-(4-chlorophenyl)ethoxy)adenosine: a adenosine A2A receptor agonist		2.8130
prasugrel hydrochloride
Prasugrel Hydrochloride: A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.. prasugrel hydrochloride : A racemate comprising equal amounts of (R)- and (S)-prasugrel hydrochloride. Used to prevent blood clots in people with acute coronary syndrome who are undergoing a procedure after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.		2.2110
n(6)-(2,2-diphenylethyl)adenosine
N(6)-(2,2-diphenylethyl)adenosine: adenosine receptor agonist; structure given in first source		2.0710
atl 313
ATL 313: A2A adenosine receptor agonist		2.0710
losartan potassium
Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.		2.1310
incretins
Incretins: Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially.		2.1310
exenatide
Exenatide: A synthetic form of exendin-4, a 39-amino acid peptide isolated from the venom of the Gila monster lizard (Heloderma suspectum). Exenatide increases CYCLIC AMP levels in pancreatic acinar cells and acts as a GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist and incretin mimetic, enhancing insulin secretion in response to increased glucose levels; it also suppresses inappropriate glucagon secretion and slows gastric emptying. It is used an anti-diabetic and anti-obesity agent.		2.1310
ConditionIndicatedRelationship StrengthStudiesTrials
Airflow Obstruction, Chronic
[description not available]		02.0510
Pulmonary Disease, Chronic Obstructive
A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.		14.0510